



Eluracat[®], a Ghrelin Receptor Agonist, Has Been Launched in France, and RaQualia Received a Lump-Sum Payment for Reaching a Milestone

Nagoya, Japan, August 29, 2024 – RaQualia Pharma Inc. (“RaQualia”) announced that it has received a notification from Elanco Animal Health Inc. (Headquartered in Indiana, U.S., “Elanco”) that Eluracat[®] (capromorelin/RQ-00000005/AT-002, “the Medicine”), a ghrelin receptor agonist RaQualia out-licensed to Elanco, has been launched in France as a medication for managing weight loss in cats with chronic conditions. As a result, RaQualia will receive a lump-sum payment upon reaching the milestone.

The Medicine is an oral liquid formulation of capromorelin, which stimulates appetite by mimicking ghrelin, a hunger hormone that promotes feeding and gastrointestinal motility. Based on its mechanism of action, weight gain in cats caused by the Medicine is thought to be due to increased food intake and metabolic changes. In the U.S., the Medicine has been marketed since 2021 under the brand name Elura[®] for managing weight loss in cats with chronic kidney disease. In Europe, Elanco obtained marketing authorization for the Medicine in 2023 and has been preparing for the launch, and the Medicine has now been launched in France under the brand name Eluracat[®]. With its launch in France, the Medicine is now being marketed in two countries. The Medicine is also approved in countries including the United Kingdom, other European nations, Brazil, Canada, and Japan, and RaQualia expects that the number of countries where the Medicine is marketed will continue to expand.

In 2010, RaQualia entered into a licensing agreement with Aratana Therapeutics Inc. (now Elanco) for the worldwide commercialization of capromorelin, the active ingredient in the Medicine, as veterinary medicines. Under the terms of the agreement, RaQualia will receive a lump-sum payment of \$2 million, which will be recorded as operating revenue for the third quarter of the fiscal year ending December 31, 2024. RaQualia will not revise its consolidated earnings forecast for the current fiscal year ending December 31, 2024, which was announced on February 14, 2024, at this time, but will promptly announce any necessary revisions to the forecast as soon as they are determined.

###

RaQualia Pharma, Inc. Media Contact:

RaQualia Pharma, Inc.

8F Meieki Southside Square, 1-21-19 Meieki Minami Nakamura-ku, Nagoya 450-0003, Japan

Tel: +81-446-6100

Email: ask@raqualia.com